JANX Q1 2023 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+28.9% YoY

Gross Profit

-$14M-674.7% margin

Operating Income

-$20M-990.3% margin

Net Income

-$17M-852.5% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-28.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$353M

Total Liabilities

$42M

Stockholders' Equity

$311M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+28.9%
Gross Profit	-$14M	-$9M	-60.8%
Operating Income	-$20M	-$14M	-49.8%
Net Income	-$17M	-$13M	-30.2%